Nitisinone Dipharma (Nitisinone)

Nitisinone works by inhibiting the enzyme 4‑hydroxyphenylpyruvate dioxygenase (HPPD), which is essential in the breakdown of the amino acid tyrosine. Blocking HPPD stops the formation of downstream toxic compounds such as fumarylacetoacetate and succinylacetone, thereby reducing the metabolic toxicity that drives the clinical manifestations of hereditary tyrosinemia type I.

The dosage of Nitisinone Dipharma is individualized and must be determined by a qualified prescriber. The treating physician will consider the patient’s age, weight, disease severity, and laboratory parameters to set an appropriate dosing regimen and adjust it as needed during therapy.

Safety data for nitisinone in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the possible risk to the fetus or infant. Healthcare providers typically evaluate each case carefully and may recommend alternative management strategies for pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

The primary alternative for hereditary tyrosinemia type I is liver transplantation, which addresses the underlying metabolic defect but carries surgical risks and long‑term immunosuppression. Nitisinone offers a non‑surgical, disease‑modifying approach that can stabilize patients and, in many cases, delay or avoid the need for transplantation. Choice of therapy depends on disease stage, patient condition, and specialist recommendation.

Nitisinone Dipharma should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity, which could affect its stability.

The medication is administered orally, usually as a tablet or capsule, and should be taken with water. It can be taken with or without food, but consistency with regard to meals helps maintain stable drug levels. Patients should follow the prescribing physician’s instructions regarding timing and any necessary dietary considerations.

Serious adverse events include hepatic failure, severe anemia, neutropenia, hypersensitivity reactions (such as angioedema or anaphylaxis), and peripheral neuropathy. Patients should be educated to report signs of liver dysfunction (jaundice, dark urine), unexplained fatigue, fever, or any allergic symptoms promptly to their healthcare provider.

Nitisinone Dipharma is contraindicated in individuals with known hypersensitivity to nitisinone or any of its excipients. It should also be avoided in patients with severe hepatic impairment where the drug’s metabolism could be compromised, and used with caution in those with significant renal dysfunction. A prescriber must evaluate each patient’s medical history before initiating therapy.